Aldeyra The (ALDX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aldeyra The (ALDX) has a cash flow conversion efficiency ratio of -0.143x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.02 Million) by net assets ($49.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Aldeyra The balance sheet quality to measure how much of total assets are equity-financed.
Aldeyra The - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Aldeyra The's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ALDX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Aldeyra The Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aldeyra The ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Greenland Energy Company Common Stock
NASDAQ:GLND
|
-0.784x |
|
Kino Polska TV SA
WAR:KPL
|
0.086x |
|
Strix Group Plc
F:SG9
|
N/A |
|
51 TALK ONL. SP.ADR A 60
F:C4G0
|
N/A |
|
Gentas Genel Metal Sanayi ve Ticaret AS
IS:GENTS
|
0.066x |
|
Tembo Global Industries Limited
NSE:TEMBO
|
0.191x |
|
Beazley plc
LSE:BEZ
|
0.120x |
|
Harn Len Corporation Bhd
KLSE:7501
|
0.080x |
Annual Cash Flow Conversion Efficiency for Aldeyra The (2011–2024)
The table below shows the annual cash flow conversion efficiency of Aldeyra The from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Aldeyra The market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.00 Million | $-43.21 Million | -0.609x | -140.38% |
| 2023-12-31 | $119.80 Million | $-30.33 Million | -0.253x | +32.50% |
| 2022-12-31 | $151.01 Million | $-56.64 Million | -0.375x | -81.32% |
| 2021-12-31 | $205.74 Million | $-42.56 Million | -0.207x | +67.17% |
| 2020-12-31 | $59.51 Million | $-37.49 Million | -0.630x | +32.66% |
| 2019-12-31 | $48.08 Million | $-44.98 Million | -0.936x | -171.42% |
| 2018-12-31 | $86.62 Million | $-29.86 Million | -0.345x | +28.99% |
| 2017-12-31 | $39.60 Million | $-19.22 Million | -0.485x | +30.62% |
| 2016-12-31 | $21.65 Million | $-15.15 Million | -0.700x | -86.93% |
| 2015-12-31 | $24.88 Million | $-9.31 Million | -0.374x | +50.75% |
| 2014-12-31 | $6.28 Million | $-4.78 Million | -0.760x | +28.08% |
| 2013-12-31 | $1.61 Million | $-1.71 Million | -1.057x | -3516.77% |
| 2012-12-31 | $-25.15 Million | $-778.05K | 0.031x | -96.98% |
| 2011-12-31 | $-2.33 Million | $-2.39 Million | 1.025x | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more